Patents by Inventor Michael Hayden

Michael Hayden has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pridopidine for the treatment of mitochondrial-associated diseases and disorders and endoplasmic reticulum (ER) stress
    Patent number: 12685725
    Abstract: The subject invention provides a method for treating a subject afflicted with a disease, disorder, or condition associated with mitochondrial dysfunction or ER stress, comprising administering to the subject a composition comprising pridopidine or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: February 23, 2021
    Date of Patent: July 21, 2026
    Assignee: PRILENIA NEUROTHERAPEUTICS LTD.
    Inventors: Michael Hayden, Michal Geva, Ana Cristina Carvalho Rego, Gerardo Lederkremer
  • Treatment of viral infection, disease or disorder using a selective sir agonist
    Patent number: 12616687
    Abstract: The subject invention provides a method for treating, reducing the incidence, suppressing or inhibiting a viral infection, disease, disorder or symptoms thereof in a subject in need thereof comprising administering to the subject a selective S1R agonist. In another aspect, the viral disease is COVID-19, and the selective S1R agonist is pridopidine or pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: November 4, 2022
    Date of Patent: May 5, 2026
    Assignee: PRILENIA NEUROTHERAPEUTICS LTD.
    Inventors: Michael Hayden, Michal Geva
  • METHOD OF TREATING AMYOTROPHIC LATERAL SCLEROSIS WITH PRIDOPIDINE
    Publication number: 20260091028
    Abstract: Provided herein is a method for treating a human subject afflicted with ALS by administering to the subject a therapeutically effective amount of pridopidine or pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 17, 2025
    Publication date: April 2, 2026
    Applicant: PRILENIA NEUROTHERAPEUTICS LTD.
    Inventors: Michael HAYDEN, Michal GEVA
  • USE OF PRIDOPIDINE FOR TREATING HUNTINGTON DISEASE
    Publication number: 20260060967
    Abstract: Provided herein a method of maintaining, improving, or lessening the decline of functional capacity, cognition, motor function, disease progression and quality of life of a subject afflicted with Huntington disease, including those afflicted with early-stage Huntington disease (HD1 and HD2, TFC 7-13) by orally administering to the subject a pharmaceutical composition comprising pridopidine or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 3, 2025
    Publication date: March 5, 2026
    Applicant: Prilenia Neurotherapeutics Ltd.
    Inventors: Michael HAYDEN, Michal GEVA
  • Use of pridopidine for treating dystonias
    Patent number: 12564582
    Abstract: The invention provides a method of treating a subject afflicted with a dystonia, comprising periodically administering to the subject a pharmaceutical composition comprising an amount of pridopidine effective to treat the subject.
    Type: Grant
    Filed: October 19, 2023
    Date of Patent: March 3, 2026
    Assignee: PRILENIA NEUROTHERAPEUTICS LTD.
    Inventors: Michael Hayden, Spyridon Papapetropoulos, Juha-Matti Savola, Eli Eyal, Beth Borowsky, Igor D. Grachev, Mark Forrest Gordon
  • Use of pridopidine for the treatment of fragile X syndrome
    Patent number: 12551474
    Abstract: The invention provides a method of treating a subject afflicted with fragile X syndrome (FXS) or a FXS related disorder, comprising periodically administering to the subject a pharmaceutical composition comprising an amount of pridopidine effective to treat the subject.
    Type: Grant
    Filed: January 31, 2022
    Date of Patent: February 17, 2026
    Assignees: PRILENIA NEUROTHERAPEUTICS LTD., NATIONAL UNIVERSITY OF SINGAPORE, - AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
    Inventors: Michael Hayden, Mahmoud Abdulhossein Pouladi, Michal Geva
  • METHOD OF TREATING AMYOTROPHIC LATERAL SCLEROSIS WITH PRIDOPIDINE
    Publication number: 20260034109
    Abstract: Provided herein is a method for treating a human subject afflicted with ALS by administering to the subject a therapeutically effective amount of pridopidine or pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 29, 2025
    Publication date: February 5, 2026
    Applicant: PRILENIA NEUROTHERAPEUTICS LTD.
    Inventors: Michael HAYDEN, Michal GEVA
  • PRIDOPIDINE FOR TREATING HUNTINGTON'S DISEASE
    Publication number: 20250360121
    Abstract: A method of treating a human patient afflicted with Huntington's disease, comprising periodically orally administering to the patient a pharmaceutical composition comprising pridopidine, its analog or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 3, 2025
    Publication date: November 27, 2025
    Applicant: Prilenia Neurotherapeutics Ltd.
    Inventors: Michael HAYDEN, Michal GEVA, Merav BASSAN, Anna Kristina VEINSDOTTER TEIGE WICKENBERG
  • PRIDOPIDINE FOR TREATING HUNTINGTON'S DISEASE
    Publication number: 20250352533
    Abstract: A method of treating a human patient afflicted with Huntington's disease, comprising periodically orally administering to the patient a pharmaceutical composition comprising pridopidine, its analog or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 3, 2025
    Publication date: November 20, 2025
    Applicant: Prilenia Neurotherapeutics Ltd.
    Inventors: Michael HAYDEN, Michal GEVA, Merav BASSAN, Anna Kristina VEINSDOTTER TEIGE WICKENBERG
  • USE OF PRIDOPIDINE AND ANALOGS FOR TREATING SYMPTOMS OF HUNTINGTON DISEASE
    Publication number: 20250319076
    Abstract: Provided herein a method of maintaining, improving, or lessening the decline of functional capacity, cognition, motor function, disease progression and quality of life of a subject afflicted with Huntington disease, including those afflicted with early-stage Huntington disease (HD1 and HD2, TFC 7-13) by orally administering to the subject a pharmaceutical composition comprising pridopidine or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: June 25, 2025
    Publication date: October 16, 2025
    Applicant: Prilenia Neurotherapeutics Ltd.
    Inventors: Michael HAYDEN, Michal GEVA
  • USE OF PRIDOPIDINE FOR THE TREATMENT OF ANXIETY AND DEPRESSION
    Publication number: 20250235441
    Abstract: The invention provides a method of reducing anxiety and/or depression in a subject comprising periodically administering to the subject a pharmaceutical composition comprising an amount of pridopidine effective to reduce anxiety and/or depression in a subject.
    Type: Application
    Filed: April 10, 2025
    Publication date: July 24, 2025
    Applicant: Prilenia Neurotherapeutics Ltd.
    Inventors: Michael HAYDEN, Mahmoud Abdulhossein POULADI
  • Low dose pridopidine for Parkinson's Disease and other diseases associated with parkinsonism
    Patent number: 12357624
    Abstract: The subject invention provides a method for treating Parkinsonism or symptoms thereof by low dose pridopidine.
    Type: Grant
    Filed: February 4, 2020
    Date of Patent: July 15, 2025
    Assignee: Prilenia Neurotherapeutics Ltd.
    Inventors: Michael Hayden, Michal Geva, Angela Cenci Nilsson
  • PRIDOPIDINE FOR THE TREATMENT OF MITOCHONDRIAL-ASSOCIATED DISEASES AND DISORDERS
    Publication number: 20250221972
    Abstract: The subject invention provides a method for treating a subject afflicted with a disease, disorder, or condition associated with mitochondrial dysfunction or ER stress, comprising administering to the subject a composition comprising pridopidine or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: February 27, 2025
    Publication date: July 10, 2025
    Applicant: Prilenia Neurotherapeutics Ltd.
    Inventors: Michael HAYDEN, Michal GEVA, Ana Cristina CARVALHO REGO
  • USE OF PRIDOPIDINE FOR TREATING FUNCTIONAL DECLINE
    Publication number: 20250082619
    Abstract: Provided herein a method of maintaining, improving, or lessening the decline of functional capacity, cognition, motor function, disease progression and quality of life of a subject afflicted with Huntington disease, including those afflicted with early-stage Huntington disease (HD1 and HD2, TFC 7-13) by orally administering to the subject a pharmaceutical composition comprising pridopidine or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 17, 2024
    Publication date: March 13, 2025
    Applicant: Prilenia Neurotherapeutics Ltd.
    Inventors: Michael HAYDEN, Michal GEVA
  • USE OF PRIDOPIDINE FOR TREATING RETT SYNDROME
    Publication number: 20240398778
    Abstract: The subject invention provides a method for treating a subject afflicted with Rett syndrome comprising administering to the subject an effective amount of pridopidine so as to thereby treat the subject.
    Type: Application
    Filed: August 25, 2024
    Publication date: December 5, 2024
    Applicant: PRILENIA NEUROTHERAPEUTICS LTD.
    Inventors: Michal GEVA, Ralph LAUFER, Michael HAYDEN
  • Use of pridopidine for treating rett syndrome
    Patent number: 12102627
    Abstract: The subject invention provides a method for treating a subject afflicted with Rett syndrome comprising administering to the subject an effective amount of pridopidine so as to thereby treat the subject.
    Type: Grant
    Filed: November 19, 2020
    Date of Patent: October 1, 2024
    Assignee: Prilenia Neurotherapeutics Ltd.
    Inventors: Michal Geva, Ralph Laufer, Michael Hayden
  • Selective Reduction of Allelic Variants
    Publication number: 20240309452
    Abstract: Disclosed herein are antisense compounds and methods for selectively reducing expression of an allelic variant of a huntingtin gene containing a single nucleotide polymorphism (SNP). Such methods, compounds, and composition are useful to treat, prevent, or ameliorate Huntington's Disease (HD).
    Type: Application
    Filed: October 16, 2023
    Publication date: September 19, 2024
    Applicants: Ionis Pharmaceuticals, Inc., The University of British Columbia
    Inventors: C. Frank Bennett, Michael Hayden, Susan M. Freier, Sarah Greenlee, Jeffrey Carroll, Simon Warby, Eric E. Swayze
  • PRIDOPIDINE AND ANALOGS THEREOF FOR THE TREATMENT OF NEURODEGENERATIVE EYE DISEASE
    Publication number: 20240261273
    Abstract: This application provides a composition comprising pridopidine or pharmaceutically acceptable salt thereof and at least one of compounds 1-8 (described herein) or pharmaceutically acceptable salt thereof for use in the treatment of neurodegenerative eye disease, symptoms thereof, and additional neurodegenerative disorders.
    Type: Application
    Filed: April 9, 2024
    Publication date: August 8, 2024
    Applicant: PRILENIA NEUROTHERAPEUTICS LTD.
    Inventors: Michael HAYDEN, Michal GEVA
  • Pridopidine for treating drug induced dyskinesias
    Patent number: 12036213
    Abstract: The invention provides a method of treating a subject afflicted with a drug-induced movement disorder including levodopa-induced dyskinesia comprising periodically administering to the subject in need thereof an amount of pridopidine or pharmaceutically acceptable salt thereof effective to treat the subject. The invention further provides a method of treating a subject at risk of developing a drug-induced movement disorder, including levodopa-induced dyskinesia.
    Type: Grant
    Filed: May 10, 2021
    Date of Patent: July 16, 2024
    Assignee: PRILENIA NEUROTHERAPEUTICS LTD.
    Inventors: Michal Geva, Aric Orbach, Michael Hayden
  • TREATMENT OF PRODROMAL HUNTINGTON DISEASE
    Publication number: 20240197708
    Abstract: Disclosed herein are methods treating prodromal HD in a subject, wherein the subject has at least 36 CAG repeats in the huntingtin (Htt) gene, wherein the method comprises administering a composition comprising pridopidine or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: April 14, 2022
    Publication date: June 20, 2024
    Applicant: Prilenia Neurotherapeutics Ltd.
    Inventors: Michael HAYDEN, Michal GEVA